Comparative cardiovascular efficacy of antidiabetic therapies in type 2 diabetes: a systematic review and network meta-analysis of randomized trials
Donya Mohammadi, Behnam Sadeghirad, Mohammad Aziz Rasouli, Lotfollah Saed, Hamid Reza Baradaran, Yousef Moradi · 2026
Read Comparative cardiovascular efficacy of antidiabetic therapies in type 2 diabetes: a systematic review and network meta-analysis of randomized trials by Donya Mohammadi, Behnam Sadeghirad, Mohammad Aziz Rasouli, Lotfollah Saed, Hamid Reza Baradaran, Yousef Moradi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13573484.txt.
Description
Donya Mohammadi, with five colleagues, presents a 2026 network review of how diabetes drugs compare on heart outcomes. Heart disease is the top killer of people with type 2 diabetes, and drug classes differ in far more than sugar control. A network method lets trials that never met head-on still be ranked through shared rivals.
Searches to the end of 2024 found 133 trials with 289,558 patients. One class, GLP-1 agonists, cut heart deaths and strokes with high-grade certainty. Another, SGLT2 blockers, cut heart failure and hospital stays for heart causes, also with high-grade certainty. A side signal that favoured a third class on heart deaths came with a warning about network imbalance. The authors urge picks matched to each patient's risk profile and costs.
Catalog record
| CREATOR | Donya Mohammadi, Behnam Sadeghirad, Mohammad Aziz Rasouli, Lotfollah Saed, Hamid Reza Baradaran, Yousef Moradi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40777 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |